[Ip-health] Infojustice Roundup - February 29, 2016

Michael Palmedo mpalmedo at wcl.american.edu
Mon Feb 29 10:19:06 PST 2016

Infojustice Roundup


Joint Submission to the UN Secretary-General's High Level Panel on Access to Medicines

[Sean Flynn, Cynthia Ho, David Levine, Gabriel Levitt, Heesob Nam, Alina Ng, and Andrew Rens] This statement calls on the High-Level Panel to promote policy coherence in the international intellectual property, human rights and global health system in part through a strong articulation and examination of the implications of the human rights duty to interpret and implement all legislation to promote the right to health and corresponding rights to access needed medicines. The submission describes why such a mandate - from the lens of international economic theory - would lead to the conclusion that states must make maximum use of routine compulsory licensing programs for pharmaceuticals to rectify intellectual property and health concerns. It then articulates how adoption of the interpretive rule should justify and motivate specific government actions - including minimizing the scope of patent rights and maximizing the use of routine compulsory licensing - that would help reduce the incoherence between rights of inventors, international human rights laws, trade rules, and public health objectives. Click here for more.<http://infojustice.org/archives/35793>


Patent Challenge Hearing on Gilead Hepatitis C Drug Sofosbuvir Starts in India

[Médecins Sans Frontières]  In proceedings that could have major implications for millions of people waiting for affordable access to a life-saving hepatitis C drug, the Indian Patent office this week will begin hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges US$1,000 per pill in the US. Today's hearings are in relation to a 'patent opposition' filed by lawyers from the Initiative for Medicines, Access & Knowledge (I-MAK) in November 2013 together with the Delhi Network of Positive People (DNP+).  In it, lawyers argued that sofosbuvir was "old science," and did not meet the standard needed for patenting in India. Click here for more.<http://infojustice.org/archives/35788>

More information about the Ip-health mailing list